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ABSTRACT: 
Introduction:  
This study sought to determine the costs of providing health care to HIV/AIDS patients in 
a tertiary level hospital in Gauteng Province. The study also determined what the 
implications were for the hospital in terms of planning and resource allocation.  
Methodology 
Study design: Retrospective Record Review 
Study Period: 03 May 2005 – 15 June 2005 
Study setting: Chris Hani Baragwanath Hospital, Gauteng. 
Study population: Medical & Pediatric inpatient discharges and deaths 
Results: 
1185 records reviewed (812 HIV positive) 
HIV positive patients were staying longer than others and costing the hospital more as 
well. Those on ARV therapy cost the most. 
Conclusion: 
More resources were being spent on HIV/AIDS patients. Increased lengths of stay and 
expenditure on drugs and investigations were the reasons for higher costs compared to HIV 
negative inpatients. Identifying ways of reducing admission and other costs must be seen as 
strategies in reducing the financial burden of HIV/AIDS to the facility. 
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CHAPTER 1 
 
1.0 INTRODUCTION 
 
1.1 Background and rationale: 
According to the Burden of Disease study done in 2000, deaths caused by HIV/AIDS 
accounted for 30% of all deaths in South Africa1, and with prevalence rates of 
approximately 11.4%, over five million South Africans are estimated to be living with the 
infection.2 Morbidity is high, and with public hospitals seeing nearly half all admissions in 
their medical wards as HIV related3, a significant portion of hospital resources is being 
spent on HIV/AIDS. By initiating the roll out of anti-retroviral therapy, the national 
government has prioritized the epidemic, budgeting R300 million for 2004/5, R600 million 
in 2005/6, and a billion rand in the 2006/7 financial years.4 However, there is no system in 
place in public hospitals to cost the health care provided to HIV/AIDS patients.  
The Chris Hani Baragwanath Hospital (CHB) in Johannesburg, South Africa is one of the 
largest hospitals in the Southern Hemisphere with nearly three thousand beds. It is an 
academic and tertiary level hospital. The hospital’s Department of Internal Medicine has 
710 beds, whilst its’ Pediatrics Department has 343 allocated beds (from monthly hospital 
nursing statistics. Provided by Nursing Director, the late Mrs M Khumalo and staff, CHB). 
What is the financial burden of HIV/AIDS in an institute of this size? The answer to this is 
crucial in that it affects budgeting and resource allocation. 
Determining financial budgets for public health hospitals is a challenge considering that 
budget allocation in South African public health sector institutes has generally always been 
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a historical incrementalist budgeting process, whereby resources for a certain year are 
allocated based on the previous year’s expenditure (usually adjusted for inflation). While 
most public sector hospitals in South Africa also generate some revenue through patient 
user fees, these amounts are insufficient to manage hospitals, and annual hospital budgets 
are allocated from the coffers of individual provinces.5 
 The historical budget allocation approach is quite rudimentary and assumes that health 
care provision does not change much over time. It does not adjust for changes in priority 
health problems or changes in population dynamics. On the other side of the spectrum lies 
zero-based budgeting, which is a more rational and comprehensive approach. This 
approach involves justifying the budget needs for any one year based on health services 
offered, health programs planned and other performance indicators. It does not rely on the 
previous year’s budget. Zero-based budgeting entails more work for managers, but it 
allows them to plan for what they are doing and what they want to do in order to cater to 
their patients’ needs.6  This latter budgeting approach was being implemented in Chris 
Hani Baragwanath Hospital at the time of the study. Therefore, for the hospital managers 
concerned, this study was imperative to determine the financial burden of HIV/AIDS to the 
institute in order to plan for the provision of HIV/AIDS services at the facility.  
 
1.2 Literature review: 
Costing the impact, direct or indirect, of HIV/AIDS on the health sector in any country is 
not an easy task. With the issue of patient confidentiality being so important in HIV/AIDS, 
it is quite difficult to determine exact numbers of people affected. Since the infection is 
also related directly or otherwise to a myriad of other illnesses, the cost implications 
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become quite complex. Nevertheless, challenges aside, it still remains crucial for health 
managers, planners and policy makers alike, to be aware of how much it costs to manage 
HIV/AIDS. Hickey, in a paper published by the Institute of Democracy (Idasa) in South 
Africa in 2003 highlighted these issues and touched on recommendations such as improved 
information management, patient tracking systems, accurate budgeting and planning, 
capacity building and the like. The paper also noted that in 2000, 24% of all public hospital 
admissions in South Africa were due to AIDS-related illnesses.7 
 
The impact of the provision of antiretroviral (ARV) therapy to HIV/AIDS patients in South 
Africa is expected to slow the progression of the disease, thus reducing hospitalization time 
and numbers of hospital visits. Since the budget for ARV therapy is allocated from a 
National ARV fund in South Africa, and not from individual hospital budgets, it is 
anticipated that adequate provision of ARV therapy, in the long run, will reduce the costs 
of management of HIV/AIDS in hospitals. Kitajima et al in Thailand attempted to estimate 
the cost savings of providing ARV therapy as opposed to the cost of not providing it in 
HIV/AIDS patients. The Highly Active Antiretroviral therapy (HAART) regimen used in 
Thailand at the time of the study was quite expensive, and so it was found that the cost of 
patients on HAART as opposed to those not on HAART was much higher. Thailand at the 
time had a universal health insurance scheme that excluded HAART from its benefits, but 
while there had been a demand to include it in the insurance package; the study found that 
a large budget would have been needed to provide the expensive HAART regime, at the 
time, to all the patients that needed it. The conclusion was that if low cost ARV therapy 
 4 
could have been provided, the costs might have been lower, but probably still higher than 
that for those not on ARV therapy.8 
 
Guinness et al from Kenya published a paper in 2002, which estimated the costs of hospital 
care for HIV positive patients compared to HIV negative patients. Research here showed 
that the costs of a specific illness-period of caring for a HIV positive patient and a HIV 
negative patient were quite similar. The reason for this was that due to limited resources, 
not much had been actively done for an HIV positive patient since drug therapy had not 
been an option at the time and diagnoses had been clinically determined. However, over a 
longer period, the study showed that costs for caring for a HIV positive patient would have 
been higher due to repeated hospital visits with more severe infections. The paper 
demonstrated the futility experienced by many health practitioners in under resourced areas 
that were unable do much for their HIV positive patients other than supportive treatment.9 
 
Hansen, Chapman & Chitsike conducted a similar study in Zimbabwe in 2000, which 
highlighted a different scenario. This paper demonstrated that the cost of caring for a HIV 
positive patient was definitely higher, in fact twice as high, than caring for a HIV negative 
patient. The fact that at the time, Zimbabwe had a resource-strong health system which 
could have afforded to manage HIV/AIDS patients at a higher level, probably contributed 
to the increased costs. The areas of increased costs identified were mainly drug-related 
(though it was not clear if this had been ARV drugs or not), laboratory costs and radiology 
costs. Longer lengths of hospital admission had not translated into increased costs as the 
expenses for HIV positive patients were found to have been more during the initial two to 
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three days of admission, since most tests etc would have been done then, and after that care 
would have been supportive in nature.10 A limitation to this Zimbabwean study was that 
the costs of admissions, in terms of staff, nutrition, facility maintenance etc, had not been 
determined. 
 
A South African study by Shisana et al, to assess the impact of HIV/AIDS on the health 
sector across the country also highlighted a number of important points. Since South Africa 
is believed to have one of the highest numbers of HIV/AIDS cases in the world, it follows 
that the epidemic would have a significant impact on its health services and the society at 
large. The article looked at the impact of the epidemic on health workers, showing definite 
losses through staff illnesses, absenteeism and low staff morale. According to this study by 
Shisana et al, about 16% of health workers in both private and public health facilities, in 
four provinces, were HIV infected. The prevalence in the younger age groups (18-35 years) 
was higher, and the article inferred that without an intervention such as anti-retroviral 
drugs, South Africa could lose the identified infected health workers to AIDS over the next 
few years. Amongst the patients surveyed in public and private health facilities (clinics and 
hospitals) across four provinces, the prevalence rate was 28%. Prevalence rates in public 
hospital facilities alone were higher, at 46% (almost twice the prevalence determined in the 
Idasa study of 2000), and since these patients stayed in hospital longer (average 13.7 days 
across all types of hospitals), this meant increased costs to the hospitals concerned. 
According to the paper, it was also noted that HIV/AIDS patients were using the bulk of 
health facility resources, at the expense of non-HIV cases.3   
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Another similar South African study by Mathabathe & Kalete, not yet published, and 
commissioned in 2004 by the Gauteng Department of Health, gave a detailed account of 
how HIV/AIDS was affecting certain aspects of hospital services in the province. The 
article looked at impacts of the epidemic on admissions, both medical and pediatric; 
impacts on length of hospital stay; and impact on costs of caring for HIV/AIDS patients at 
eight hospitals in the province. Of relevance to the subject of this report, was the fact that 
Mathabathe et al determined a cost of care provided to adult HIV/AIDS patients at tertiary 
hospitals (R 1038.36), however the limitation was that this only included costs for drugs, 
laboratory and radiological investigations. Also interestingly, the average length of stay in 
tertiary hospitals (5.1 days) was cited to be shorter compared to other levels of care.11 
 
Also of relevance to this study was a similar project conducted at Chris Hani Baragwanath 
hospital in 1996 that attempted to quantify costs of inpatient care of HIV infected patients. 
The paper by Karstaedt et al demonstrated the common conditions that HIV infected 
patients were being admitted for in the hospital, being mainly tuberculosis, acute 
pneumonias and gastroenteritis. The authors also used a similar methodology in 
determining costs, including the use of the bed-day cost (patient-day-equivalent cost), drug 
costs and investigation costs. More than 70% of the total cost of an admission was found to 
have been due to the bed-day cost. The average length of an admission was found to have 
been 9.8 days across all stages of HIV infection. The costs were calculated per patient per 
year, using the World Health organization staging for HIV/AIDS, and included all the 
recurrent admission costs for that year. The costs for Stage I patients were found to have 
been R910/year, R1277/year for Stage II, R2161/year for Stage III, and R6783/year for 
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Stage IV.12 The differences with the current study (subject of this dissertation) were that in 
the Karstaedt et al study, records of only adult medical patients had been assessed for 
annual costs of all admissions per patient, and ARV therapy was not part of any treatment 
regimen at that time. 
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CHAPTER 2 
 
2.0 MATERIALS & METHODS 
 
2.1 Aim: 
To estimate the total costs of caring for hospitalized patients with HIV/AIDS in the 
Medical and Pediatric wards of Chris Hani Baragwanath Hospital during the period May-
June 2005. 
 
Specific objectives: 
• To determine direct costs such as lab investigations, procedure costs and 
pharmaceutical costs 
• To determine a patient-day equivalent cost that covered overheads, staff salaries, 
consumables, and non-consumables 
• To determine average lengths of stay of HIV positive and HIV negative patients 
• To compare costs of care at Level 1 wards and Tertiary care wards 
• To estimate the costs of providing care to HIV positive patients (not on ARV 
therapy) in comparison to HIV negative patients  
• To compare costs of the HIV/AIDS patient (not on ARV therapy) to that of a 
patient on ARV therapy 
• To estimate costs of HIV/AIDS cases as per discharge/death diagnosis 
• To determine the proportion of the cost of care to HIV positive patients in relation 
to the total hospital budget for the period May-June 2005  
 9 
2.2 Methodology: 
Study Design: Record review of discharges and deaths of inpatients from the Internal 
Medicine and Pediatric departments over a period of six weeks. 
Study setting: Medical and Pediatric wards, Chris Hani Baragwanath Hospital, 
Johannesburg 
Study population: all inpatients seen in the Medical and Pediatric departments at the 
hospital 
Study period: Six weeks (03 May – 15 June 2005) 
Sampling:  
Of the 8722 admissions seen at the hospital (in Medicine & Pediatrics) during the months 
of May and June 2006, 4020 records of discharges and deaths from the two concerned 
departments were directed to the principal investigator’s office over the six weeks of the 
study. From these records, 812 HIV positive records were determined to be ‘complete’, and 
all of them were reviewed. The ‘complete’ records of non-HIV patients were sampled 
through systematic random sampling (every fifth record was selected), and resulted in 373 
such records being reviewed for the study. Any incomplete record was excluded from the 
review. Eventually 2835 records were excluded for either ‘being’ incomplete, or unselected 
non-HIV records.  
‘Complete’ records were defined as those with the following: 
- Patient details,  
- Doctors’ notes  
- Nursing notes  
- Treatment details (drugs, dosages and days on treatment) 
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- Investigation details 
If any of the above were missing, or if the information in the record could not provide the 
required data, the record was considered ‘incomplete’ and not included in the study. 
In addition, HIV status was determined either by the clinician’s discharge/death diagnosis 
and/or by the results of an HIV test in the patient file. 
 
 
 
 
 
 
 
                                                                        
 
 
Study period was 6 weeks, so less records                          Only ‘complete records’ were selected 
were available for review. In addition, some records          i.e. all ‘complete’ HIV positive patient  
were still in wards, or were lost or misplaced.                    files and HIV negative patient 
So 4702 records could not be accessed by the                    files were randomly selected. 
investigators due to the mentioned reasons.                        2835 records were excluded for being           
                                                                                             either ‘incomplete’ records or  
                                                                                             unselected HIV negative records                                                                              
Figure 2.2.1: Record selection and flow 
 
 
2.3 Ethical considerations:  
All information was collected anonymously in the data collection sheet, and respected 
patient confidentiality. (See Appendix II) 
Permission was obtained from the Human Research Ethics Committee (Medical) of the 
University of Witwatersrand (See Appendix III), as well as from the management of the 
hospital concerned. The Gauteng Health Department also approved the study.  
 
 
 
8722 records of 
discharges & deaths seen 
in hospital over 8 weeks 
4020 records sent to 
office for review 
1185 records finally 
reviewed. 
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2.4 Data Collection and Management: 
The records from patients in the Medical and Pediatric departments, discharges and deaths, 
were collected each day by the area staff normally handling patient files, and directed to 
the office of the principal investigator. The files were then reviewed for HIV status, and 
utilization data extracted by the principal investigator and two researchers (retired nurses) 
on a data collection sheet. The costs of investigations, drugs, details on hospital expenses 
and the like were sourced from various departments and documents, as listed in Table 
2.4.1.  
Each item as indicated in the source document, be it drug or investigation, was specifically 
coded, the cost data calculated (see Appendix I) and then the relevant patient item entered 
onto the data collection sheet. The data collection tool/sheet (Appendix II), was developed 
by the data management team of the Perinatal HIV Research Unit (PHRU), who were also 
collaborators in this study. The patient details were linked to the data collection sheet with 
the hospital number only, and no patient names were entered in the data collection sheet. 
The records were reviewed from 03 May 2005 till 15 June 2005. 
The data sheets were then entered into Datafax, an electronic character recognition system, 
used by the PHRU, and the data captured on their database. 
     
 
 
 
 
 
 
 
 12 
Table 2.4.1: Sources of data 
Sources of data for cost analysis: Data extracted from the sources: 
National Health Laboratory System.1 Costs of Laboratory investigations 
Provincial Gazettes.13 Costs of Radiology & other investigations 
• Pharmacy price lists.14 
• Price Lists from the procurement section 
for items such as intravenous fluids, drip 
sets and the like.2 
Costs of drugs and other items 
Patient records 
 
- Diagnosis on discharge/death, CD4 count value 
per patient, investigation & treatment details etc 
- Lengths of Stay 
• Financial expenditure sheets from the 
office of the Director of Finance at the 
institute.3 
• Hospital statistics department 
Data of Hospital expenditure on staff, 
investigations, drugs, numbers of patients seen 
and the like to calculate the cost of a Patient Day 
Equivalent (PDE)  
 
2.5 Calculation of Patient Day Equivalent Cost (PDE)15: 
The PDE cost was the hospital cost of caring for an inpatient on a daily basis, and included 
the cost of personnel (doctors, nurses & other health workers), food, space, building 
maintenance and the like.  
The formula used by provincial hospitals for calculating a PDE cost was: 
     PDE cost = Total Hospital expenditure∗ 
(Total inpatient days+ [0.5 x Day patients] + [Total outpatient & casualty headcount x 0.33]) 
 
Table 2.5.1: Data for PDE cost calculation for the study period (May-June 2005) 
Average number of Inpatient days/month 65479 
Average number of Day patients/month 2799 
Average Total outpatient & Casualty 
headcount/month 
82891 
Average Total expenditure/month* R57 377 467 
Average PDE cost/month R609 
 
                                                 
1
 Provided by Dr Mbele and staff, National Health Laboratory services, Chris Hani Baragwanath Hospital as 
communicated to Dr Manning, Clinical Director CHB (May 2005) 
2
 Provided by Mr G Viviers, Deputy Director, Procurement, CHB (April 2005) 
3
 Provided by Mr S Van Vuuren , Acting Director of Finance, and Mr P Nortje, Deputy Director of Finance, 
CHB (May 2005) 
∗
 In this study, the total hospital expenditure excluded all laboratory, procedure, blood bank and pharmacy 
costs. These excluded costs were calculated separately per individual patient in the study.  
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Therefore, the PDE cost calculated in this study was R609/day, according to the above 
formula. 
The expense per patient, therefore, consisted mainly of three types of costs: 
• Cost of drugs, intravenous (IV) fluids and other pharmaceuticals. 
• Cost of laboratory investigations, radiological investigations and 
other procedures 
• Cost of the length of stay (PDE cost in Rands x length of stay in 
days) 
The above three categories of costs were added up to give a total cost per patient to the 
hospitalϕ. 
 
2.6 Statistical analysis 
The data in the PHRU database was then exported to MS Excel, and analysis done using 
Epi Info Version 3.2 and SPSS software. The tests used to determine statistical significance 
were One-way ANOVA with post-test (Tukey) for more than three groups of data, and 
unpaired ‘t’ test when two groups of data were compared. The main outcome measures 
were average length of stay per patient, average costs per patient for procedures and 
pharmacy services, and average total cost. Differences in values were considered 
statistically significant if the ‘p’ value was less than 0.05. 
 
 
                                                 
ϕ
 It must be noted that costs calculated from this study were different to what the hospital billed each patient, 
the assumption being that the hospital was not actually billing the true cost of patient care, since user fees are 
heavily subsidized. This study attempted to find out what those true costs were. 
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2.7 Pilot Study: 
A Pilot study was conducted over a brief period i.e. a few days prior to the commencement 
date. 
Issues identified during the pilot: 
• Longer list of drugs and investigations had to be considered in terms of identifying 
costs 
• Larger than predicted numbers of records were being seen every day, close to 100-
150 records were being reviewed daily, so eventually all ‘complete’ HIV records 
collected during that period were reviewed, and the ‘complete’ non-HIV records 
had to be sampled (systematic random sampling). ‘Incomplete’ records were not 
reviewed. 
• More than one researcher was needed (eventually 2 retired nurses were employed). 
• Extra time for backlogs had to be factored in, due to the large numbers of records 
seen.  
• The data sheet had to be changed three times to accommodate added data. (See 
final data collection sheet attached as Appendix II). 
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CHAPTER 3 
 
3.0 RESULTS:  
Over an eight-week period from the beginning of May until the end of June 2005, 8722 
Medical and Pediatrics patients were processed as discharges or deaths from the Chris Hani 
Baragwanath Hospital (Provided by Ms Joyce, CHB statistics department). Of these, 4020 
records were sent to the principal investigator’s office during the six weeks of the study 
duration, and from these 1185 complete records were reviewed. 
 
3.1 Characteristics of patients reviewed: 
The following tables illustrate the demographic and other details of the patients reviewed. 
Table 3.1.1 below describes the numbers of patients seen in terms of gender, age group, 
HIV status, and ARV therapy. 
Table 3.1.1: General details: 
Number of records reviewed (n) 1185 
Female patients 631 (53%) 
Male patients 554 (47%) 
Adults  800 (67.5%) 
Children (Age < 14 years) 385 (32.5%) 
HIV positive patients 812 (68.5%) 
HIV negative patients 279 (23.5%) 
Unknown HIV status 94 (8%) 
HIV positive patients on ARV therapy 77 (9%) 
HIV positive patients not on ARV therapy 735 (91%) 
 
Table 3.1.2 below illustrates the profiles of gender and age group in relation to HIV status. 
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Table 3.1.2: Profile of patients: 
 Total (n) Male (%) Female (%) Average age Median Age 
Children      
HIV positive 287 161 (56%) 126 (44%) 1.7 years 8 months  
HIV negative 98 54 (55%) 44 (45%) 3 years 1 year  
Adults       
HIV positive 525 230 (44%) 295 (56%) 36.5 years 35 years  
HIV negative 181 77 (43%) 104 (57%) 45.9 years 44 years 
Unknown HIV 
Status 
94 32 (34%) 62 (66%) 44.5 years 41 years 
 
Table 3.1.3 demonstrates cost differences between HIV positive and negative patients with 
respect to average length of stay, costs of drugs, procedures and the like. 
 
Table 3.1.3: General cost differences between HIV Positive & HIV Negative patients 
 
 HIV Positive cases 
(n = 812)  
HIV Negative cases 
(n = 279) 
Unknown HIV status 
(n = 94) 
Average Length of stay per patient 
 
9.5 days 
 
 
7 days 
 
 
7.5 days 
Average cost of Procedures, lab 
tests etc 
R 1134.49 
(n=812) 
[15% of total patient 
cost] 
R 978.16 
(n=279) 
[18% of total cost] 
R 1107.35 
(n=93)*  
[18% of total cost] 
Average cost of drugs, fluids etc R 587.48 
(n=758)* 
[8% of total cost] 
R 259.16 
(n=265)* 
[5% of total cost] 
R 415.03 
(n=85)* 
[7% of total cost] 
Cost of Length of stay (PDE cost 
x length of stay) 
R5766 
[77% of total cost] 
R4265.2 
[78% of total cost] 
R4548 
[76% of total cost] 
Average total cost to hospital per 
patient 
R7448.9 
 
 
R5489.5 
 
 
R6018.9 
* (‘n’ was reduced in the instances where drugs were not prescribed or procedures were not done for a particular patient) 
Sums of the percentage proportion costs slightly exceed 100% as figures have been rounded off. 
 
From  Table 3.1.3, one could observe that HIV positive cases were, on average, staying 
more than two days longer than HIV negative cases (p < 0.001), which was considered 
statistically significant. Likewise, the average total cost of treating an HIV Positive case 
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was also considerably higher than treating an HIV Negative case (p < 0.001).  The cost of 
drugs and fluids was found to more than double for an HIV Positive patient as compared to 
an HIV Negative patient (p<0.001).  
It could be clearly noted from Table 3.1.3, that more than 75% of the total hospital cost 
was the cost of the length of stay. 
Table 3.1.4 below showed the total amounts spent in the hospital during the study period 
with regards to drugs, procedures and total costs. This applied to the 812 HIV positive 
patients reviewed. 
Table 3.1.4: Total hospital expenditure for the study period: HIV positive patients 
 HIV positive (n=812) 
Sum costs of all drugs, fluids etc R445 309 
Sum cost of all investigations R921 214 
Total cost to hospital (including cost of length of stay)  
R6 048 515 
 
The patients reviewed in this study were those who were admitted and discharged from the 
medical and pediatric departments at the hospital, and had therefore received tertiary level 
health care services. However, as part of a strategy to reduce the patient load on the main 
wards of the Medical department, some wards within the department had been identified to 
offer a service meant mainly for those patients who were not critically ill but who may 
have needed short stay admissions under the care of doctors. These other wards were 
labeled as Level 1 services (or Primary care wards), i.e. a step-down area within the tertiary 
institute itself. Adult patients were therefore admitted to both tertiary medical and Level 1 
wards, whilst children only to tertiary care pediatric wards. 
In the following graphs and tables, patients have thus been grouped according to: 
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• Those admitted and discharged from tertiary care wards, and if HIV positive, not on 
anti-retroviral therapy 
• Those admitted and discharged from Level 1 wards, and if HIV positive, not on 
anti-retro viral therapy 
• HIV positive patients on anti-retroviral therapy discharged either from tertiary or 
Level 1 wards. 
 
3.2 General Lengths of stay 
The following table illustrated the average lengths of stay for patients in relation to gender, 
age group and if on ARV or not. 
Table 3.2.1: Length of stay (LOS) for patients 
   n Average LOS  & 
(Standard deviation) 
Tertiary care wards (not on ARV)   
males 146 10.2 days (7.2) HIV+ females 191 9.8 days (8.6) 
males 72 7.5 days (8.4) Adult HIV- females 90 8.2 days (7.9) 
males 149 8.2 days (6.9) HIV+ females 112 8.8 days (7.5) 
males 54 6.2 days (5.6) Pediatric HIV- females 44 6.6 days (7.2) 
Level 1 wards (not on ARV)   
HIV positive cases 137 6.2 days (4.7) Adult HIV negative cases 19 2.9 days (3.4) 
Patients on anti-retro virals   
Adult 51 13.6 days (12.8) 
Pediatric 26 22.5 days (38.1) 
 
In tertiary wards, the LOS of HIV infected male adults who were not on ARV’s was two 
days longer than HIV uninfected males (p=0.02). Likewise, HIV infected children were 
admitted two days longer than uninfected children, but this comparison was not statistically 
significant. All patients on anti-retrovirals had markedly longer LOS than HIV infected 
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patients not treated with ARV’s (p<0.0001).  In addition, HIV positive adult patients 
admitted in the tertiary wards had longer admissions than those in Level 1 wards 
(p=0.004).  
 
3.3 Common conditions in all patients: 
The following figures, 3.3.1 and 3.3.2, illustrated the common conditions in adults and 
children on discharge or death during the study period. 
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Figure 3.3.1: Common conditions in HIV infected adults 
 
Figure 3.3.1 shows the leading conditions which HIV positive adults were being 
discharged with at the hospital. Tuberculosis (both pulmonary and extra-pulmonary) was 
the leading diagnosis and comprised 43% of all adult HIV infected patients (mainly tertiary 
ward cases) not treated with ARV’s.  Leading diagnoses in tertiary care HIV negative 
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adults were mental illness (15% of adult HIV negative discharges), cardiac disease (14%) 
and hypertension (11%). Level 1 HIV negative patients who were discharged had mainly 
asthma (26% of Level 1 HIV uninfected discharges), pneumonia (16%) and gastroenteritis 
(11%).   
 
0
5
10
15
20
25
30
35
40
% of patients
PTB Pneumonia HIV Wasting
disease
Gastro
enteritis
Respiratory
tract disease
Neonatal
sepsis
HIV Positive (not on ARV)
HIV Negative
 
Figure 3.3.2: Common discharge diagnoses in children 
 
Figure 3.3.2 shows the common conditions children were being discharged with in tertiary 
care wards, excluding those on ARV therapy. Pneumonia and Gastroenteritis were the 
commonest conditions in HIV infected children. Amongst children who were on ARV 
therapy, the common discharge conditions were very similar to those not on therapy. 
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3.4: CD4 counts and common discharge conditions: 
The following graph shows the common discharge conditions as per CD4 count range. 
Only 287 HIV positive patients in the study group had CD4 values recorded in their files. 
More than half those patients with CD4 counts less than fifty had been discharged with 
pulmonary tuberculosis, indicating that this was the common condition sicker patients were 
being admitted and discharged for.  
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Figure 3.4.1:  CD4 counts and common discharge conditions  
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3.5: General Comparison of costs 
The following table illustrated the average costs of drugs, procedures, length of stay, and 
total costs of patients in tertiary care and Level 1 wards.  
Table 3.5.1: General Comparison of average costs.  
 
  
Cost of    
LOS 
  Cost of drugs    Cost of investigations   Total costs 
 
HIV Positive 
adults (Tertiary 
care) Male R 6,232 R 762 R 1,289 R 8,256 
  Female R 5,943 R 899 R 1,323 R 8,095 
HIV Positive 
Children 
(Tertiary care) Male  R 5,019 R 270 R 1,149 R 6,427 
  Female R 5,329 R 147 R 1,072 R 6,533 
HIV Negative 
adults (Tertiary 
care) Male R 4,559 R 245 R 1,264 R 6,048 
  Female R 4,974 R 259 R 1,049 R 6,273 
HIV Negative 
Children 
(Tertiary care) Male R 3,756 R 452 R 924 R 5,107 
  Female R 4,042 R 93 R 737 R 4,869 
  
Patients on 
ARV's R 10,116 R 821 R 1,566 R12, 471 
  
HIV Positive 
Level 1 patients R 3,747 R 533 R 500 R 4,725 
  
HIV Negative 
Level 1 patients R 1,763 R 163 R 271 R 2,188 
 
Table 3.5.1 showed that HIV positive patients on ARV therapy had considerably higher 
costs of length of stay, due to their increased duration of stay (p<0.001), compared to the 
other patients. (Refer Table 3.2.1 for lengths of stay) 
HIV positive adult patients had significantly more spent on drugs compared to adult HIV 
negative patients, or children (p<0.001). Patients on ARV therapy also had more spent on 
drugs compared to children, and adult HIV negative patients (p<0.001). The other 
observed differences were not statistically significant. 
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Table 3.5.1 again clearly demonstrated that the bulk of the total hospital cost was the cost 
of the length of stay (over 70% of total cost), indicating that the longer a patient was 
admitted, the higher the cost was to the hospital. Drugs and investigations contributed to a 
much lower proportion of the total costs (approximately 20-30%).  
Patients on ARV therapy also had more than three times the amount being spent on 
investigations compared to Level 1 patients (p<0.001). Patients admitted and discharged 
from the tertiary care wards also had higher costs of investigations compared to Level 1 
cases (p<0.001). 
The last column in Table 3.5.1 denoted the average total cost of the patients. Patients on 
ARV therapy clearly had the highest total costs compared to Level 1 HIV positive patients 
and tertiary care patients (p<0.0001). Tertiary care patients also had significantly more 
total costs than Level 1 cases (p<0.001). 
The mean cost of care of all HIV negative adult patients during admission was significantly 
less than the mean cost of all HIV infected patients (p<0.001).  Similarly for children, the 
mean cost of admitting an HIV infected child was comparatively higher than for the 
negative child (p>0.05). 
Death was recorded in fifty-one records of which 49% were adults and 51% were children.  
Of the total deaths, 94% were HIV infected, but this high percentage was obviously due to 
the focus of the study.  There was no statistically significant difference in costs (p>0.05) 
between those who had died and those who had survived their admissions.     
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3.6: Tertiary care patients: 
Tables 3.6.1 and 3.6.2 show lengths of stay and costs for HIV positive patients in tertiary 
care wards, per diagnosis. Table 3.6.3 indicated cost drivers for this category of patients. 
Table 3.6.1: LOS for common conditions among HIV positive patients in tertiary care wards 
Diagnosis Age 
group 
Number of 
patients (n) 
Average LOS & 
(Standard 
deviation) 
Tertiary care wards: HIV positive cases (not on 
ARV) 
   
PTB Adult 120 9.7 days (7.8) 
 Child 26 9.7 days (7.9) 
Pneumonia Adult 29 9.4 days (5.3) 
 Child 98 7.8 days (6.4) 
Extra pulmonary TB  Adult 31 9.5 days (4.5) 
 Child 7 10.4 days (8.1) 
Gastroenteritis Adult 11 8.9 days (4.8) 
 Child 51 7.5 days (7.9) 
Cryptococcal meningitis Adult 38 11.1 days (7.9) 
 Child 1 15 days (0) 
HIV Wasting disease Adult 22 9.1 days (5.7) 
 Child 23 11 days (8.7) 
 
From the findings in Table 3.6.1, tertiary care patients with cryptococcal meningitis were 
staying longer than those with the other mentioned conditions (adult cases more than three 
days longer than those with gastroenteritis and pneumonia, p>0.05). 
Table 3.6.2: Average costs of care among HIV positive patients in Tertiary wards  
Diagnosis Age 
group Cost of 
LOS 
Cost of 
drugs 
Cost of 
investigations 
Total 
costs 
(ZAR) 
Tertiary care wards: HIV 
positive cases (not on ARV) 
 
    
PTB Adult R5912 R864 R1204 R7944 
 Child R5879 R249 R1338 R7456 
Pneumonia Adult R5691 R691 R1233 R7567 
 Child R4754 R156            R955 R5854 
Extra pulmonary TB  Adult R5756 R1212 R1062 R7913 
 Child R6351 R117 R1674 R8139 
Gastroenteritis Adult R5426 R787            R790 R7002 
 Child R4538 R159 R1160 R5842 
Cryptococcal meningitis Adult R6747 R1188 R1362 R9234 
 Child R9135 R266 R2969 R12369 
Wasting disease Adult R5508 R714 R1610 R7800 
 Child R6673 R213 R1315 R8182 
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There were some difference in costs of lengths of stay in the various conditions (p>0.05). 
The cost of drugs in adult patients with PTB was more than five times that of children with 
Pneumonia (p<0.01). Children discharged with Gastroenteritis and Pneumonia had the 
least cost for drugs compared to other conditions and age groups (p<0.05). There were no 
statistical differences in the costs of investigations. However, an adult admitted and 
discharged with cryptococcal meningitis in tertiary care wards was costing the hospital 
significantly more compared to a child with pneumonia (p<0.05). 
Table 3.6.3: Cost drivers in Tertiary wards: 
 
    
Most commonly 
used 
pharmaceuticals 
Pharmaceutical 
cost drivers 
Most 
common 
procedures 
Cost drivers in 
Procedures 
HIV 
positive  Adults 
Antibiotics e.g. 
(Augmentin, 
Bactrim, Ciprobay, 
Flagyl etc), 
Paracetamol, 
Fungizone, IV fluids, 
Anti-TB drugs 
Antibiotics, IV 
fluids, 
flucanozole, 
acylovir, blood 
transfusion 
CXR, CD4 
counts, FBC, 
U&E, TB 
tests (Sputum 
AFB, & TB 
Bactec) 
Scans (CT scan, MRI, 
Ultrasounds etc), 
Special procedures 
(Gastroscopy, 
Bronchoscopy, EEG, 
EMG etc), Thyroid 
function tests, LFT, 
HIV PCR 
  Children 
Antibiotics 
(Gentamycin, 
ampicillin, bactrim, 
penicillin, etc), 
Flucanozole, 
Nystatin, Prednisone 
Blood transfusion, 
acyclovir, 
antibiotics, 
quinine, IV fluids 
CXR, FBC, 
U&E, HIV 
tests (Elisa & 
PCR), C-
reactive 
protein 
Scans (CT, 
ultrasound/USS), 
Special procedures 
like gastric washings, 
Fine needle aspiration 
cytology), HIV PCR, 
LFT, U&E 
HIV 
Negative Adults 
Antibiotics, anti-
hypertensives, IV 
fluids, paracetamol, 
Furesemide 
Blood 
transfusions, IV 
fluids, antibiotics, 
Heparin & 
Haloperidol 
injections 
CXR, FBC, 
U&E, LFT, 
Blood 
glucose 
Scans, special 
procedures, 
hemodialysis, HIV 
PCR 
  Children 
Antibiotics, 
paracetamol syrup, 
nystatin, prednisone, 
anti-TB drugs 
Antibiotics, IV 
fluids, blood 
transfusion, 
Digoxin 
FBC, U&E, 
CXR, C-
reactive 
protein, blood 
culture 
Scans (Echo, CT, 
USS),Special 
procedures (gastric 
washings, cardiac 
catheterization etc), 
HIV PCR, LFT 
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The above table illustrates the common procedures and pharmaceuticals that were utilized 
by tertiary care patients, as well as the cost drivers.  
 
3.7: Level 1 wards: 
  
Tables 3.7.1, 3.7.2 and 3.7.3 demonstrated lengths of stay, costs and cost drivers in patients 
discharged from Level 1 wards at Chris Hani Baragwanath hospital during the study 
period. 
 
Table 3.7.1: LOS of common conditions admitted and discharged from Level 1 wards 
Diagnosis Age group n Average LOS & (Standard deviation) 
Level 1 HIV positive cases (not on ARV)    
PTB Adult 52 5.8 days (4.4) 
Pneumonia Adult 29 5.8 days (4.3) 
Gastroenteritis Adult 19 5.8 days (4.7) 
Cryptococcal meningitis Adult 10 6.1 days (3.3) 
Wasting disease Adult 7 5.7 days (1.5) 
 
Table 3.7.1 showed that HIV positive cases were being admitted for more or less similar 
durations, irrespective of diagnosis (p>0.05). Likewise, costs were similar too, with no 
significant differences. 
Table 3.7.2: Average costs of common conditions in Level 1 wards 
Level 1 HIV positive cases (not 
on ARV) 
 Cost of 
LOS 
Cost of 
drugs 
Cost of 
investigations 
Total 
costs 
PTB Adult R3549 R567 R402 R4464 
Pneumonia Adult R3549 R478 R521 R4499 
Gastroenteritis Adult R3526 R505 R460 R4465 
Cryptococcal meningitis Adult R3715 R659 R505 R4747 
Wasting disease Adult R3480 R945 R442 R4732 
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Table 3.7.3: Cost drivers in Level 1 wards 
    
Most common 
pharmaceuticals 
Pharmaceutical 
cost drivers 
Most 
common 
procedures 
Cost drivers in 
Procedures 
HIV 
positive  Adults 
Antibiotics, 
Flucanozole, IV 
fluids, Anti-TB 
drugs, Imodium 
Antibiotics, IV 
fluids, Flucanozole, 
Blood transfusion, 
Keyexalate 
FBC, U&E, 
CXR, CD4 
counts, TB 
tests (sputum 
AFB & TB 
Bactec) 
USS, Special 
procedures 
(Hemodialysis, 
gastroscopy, 
FNAC), HIV 
PCR, viral loads, 
LFT 
HIV 
Negative Adults 
Antibiotics, IV 
fluids, anti-TB drugs 
Antibiotics, IV 
fluids, Anti-
epileptics (Rivotril, 
Phenytoin IV) 
FBC, U&E, 
CXR LFT, CXR, U&E 
 
Cost drivers in Level 1 patients were also similar to tertiary care cases. 
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3.8: Patients on ARV therapy: 
The following three tables demonstrated lengths of stay, costs and cost drivers for patients 
on ARV therapy.  
Table 3.8.1: LOS in patients on ARV therapy 
Diagnosis Age group n Average LOS & (Standard deviation) 
Patients on ARV therapy    
PTB Adult 14 20 days (18) 
 Child 8 19.3 days (12.8) 
Pneumonia Adult 6 15 days (11.6) 
 Child 8 41.3 days (64.2) 
Gastroenteritis Adult 5 5.8 days (4.3) 
 Child 3 5.7 days (0.6) 
Cryptococcal meningitis Adult 6 15.5 days (9.7) 
 Child 0  
Wasting disease Adult 5 13.4 days (12.6) 
 Child 1 51 days (0) 
 
From Table 3.8.1, it could be observed that, excluding those patients with gastroenteritis 
and HIV Wasting disease, those with other conditions were staying longer (p>0.05).  
 
Table 3.8.2 Average costs of common conditions in those on ARV therapy 
Patients on ARV therapy Age 
group 
Cost of 
LOS 
Cost of 
drugs 
Cost of 
investigations 
Total 
costs 
PTB Adult R12267 R769 R1298 R14333 
 Child R11723 R599 R1226 R13548 
Pneumonia Adult R9135 R1175 R1744 R12053 
 Child R25121 R1642 R2813 R29370 
Gastroenteritis Adult R3532 R315 R458 R4305 
 Child R3451 R203 R1241 R4895 
Cryptococcal meningitis Adult R9440 R1727 R1238 R12117 
Wasting disease Adult R8161 R521 R3508 R12189 
 Child R31059 R1235 R2859 R35152 
 
From the above table, the most significant difference was that the hospital was spending 
almost eight times more on investigations in adults with HIV Wasting disease, as opposed 
to those admitted and discharged with Gastroenteritis (p<0.05). 
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Table 3.8.3 Cost drivers in patients on ARV therapy 
  
Most common 
pharmaceuticals 
Pharmaceutical cost 
drivers 
Most common 
procedures 
Cost drivers in 
Procedures 
HIV 
positive 
adults & 
children 
Antibiotics (Augmentin, 
Bactrim, Flagyl, Ciprobay 
etc), Anti-TB drugs, IV 
fluids, Flucanozole, 
ARV’s (Stavudine, 
Efavirenz, Lamivudine 
etc) 
Antibiotics, ARV's, 
IV fluids, blood 
transfusions, 
flucanozole 
FBC, U&E, 
CXR, LFT, 
blood cultures 
Scans, Special 
procedures (FNAC, 
gastroscopy, 
bronchoscopy etc), 
LFT, HIV PCR, 
Thyroid function 
profiles 
 
3.9: Areas of increased expenditure: 
The following table showed the distribution of costs per drug between HIV positive and 
non-HIV cases. The figures indicated that the cost per HIV positive patient was much 
higher than for the non-HIV patient (which included the HIV negative and ‘Unknown’ 
status cases). 
Table 3.9.1: Pharmaceutical Cost per patient 
Amounts spent in Rands/ per 
patient for: 
HIV positive (n=812) Non-HIV cases (n=373) 
Intravenous fluids R95/patient R69/patient 
Augmentin R64/patient R62/patient 
Flucanozole R50/patient R19/patient 
Acyclovir R26/patient R1/patient 
 
Table 3.9.2: Frequency of investigations 
Common Investigations/per 
patient 
HIV positive cases (n=812) non-HIV cases (n=373) 
CT Scan 1 scan done for every 11 cases 
(Total 71 scans) 
1 scan for every 9 patients 
(Total 41 scans) 
Chest X-ray 1 X-ray per patient 
(Total 755 X-rays) 
1 X-ray per patient 
(Total 259 X-rays) 
Full blood count Nearly 2 tests per patient 
(Total 1174 tests) 
1 test per patient 
(Total 473 tests) 
Liver Function test 1 test for every 2 patients 
(Total 357 tests) 
1 test for every 3 patients 
(Total 128 tests) 
HIV PCR test 1 test for every 6 cases 
(Total 135 tests) 
1 test for every 18 patients 
(Total 21 tests) 
Urea & Electrolytes 
 
2 tests per patient 
(Total 1475 tests) 
 1 test per patient 
(Total 536 tests) 
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Table 3.9.2 also showed the frequencies of investigations per patient, for both HIV positive 
and non-HIV cases.  
Both the above tables listed items that had been identified as significant cost drivers in this 
paper. It was thus observed that HIV positive patients were using more of the above-
mentioned resources than the non-HIV cases. 
 
3.10 Budget implications 
 
One of the key objectives of this study was to determine the financial burden of HIV/AIDS 
for the institute and the implications of the findings in terms of budget planning and 
resource allocation. Attempting to determine the cost burden of HIV/AIDS for this institute 
was quite complex, considering that exact numbers of HIV/AIDS cases admitted to the 
overall hospital were not clear. The study results managed to provide an estimate of what 
the average cost of an HIV infected patient was for the institute and what the average 
length of stay was.  
By using data collected by nursing staff in the institute of daily head counts of HIV 
positive patients (adults and children) across all the departments, and using the average 
length of stay for HIV positive patients determined in this study, for both adults and 
children (calculated as 9.5 days), it was possible to determine an approximation of the 
number of HIV positive cases seen during January to July 2005 throughout the entire 
hospital.  
 
Actual numbers of patients =         Total number of patients days 
                                                
                                                                              Average length of stay 
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Once the actual numbers were calculated, the average cost per HIV positive patient 
estimated in this report was used to determine the proportion of the total hospital 
expenditure that could be attributed to HIV/AIDS, as illustrated in Figure 3.10.2.  
Figure 3.10.1 below showed that approximately 600-800 HIV positive patients (both 
children and adults) were being admitted per month in the entire hospital, in 2005.  
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Figure 3.10.1 Burden of HIV/AIDS 2005 
 
Figure 3.10.2 illustrated the amount in millions of rands spent on HIV positive cases in 
2005. Although some of the prices used in this study were 2004 and earlier prices, this was 
assumed to be current for the cost calculation in 2005, as used by the institute. 
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Figure 3.10.2: Costs of HIV positive cases in 2005 
 
In 2005 amounts ranging between R5 million to R6 million was being spent each month on 
HIV/AIDS inpatients, which was approximately 6% of the monthly hospital expenditure.∗ 
The cost of the 812 HIV positive patients included in this report contributed to roughly 
7.5% of the average monthly expense, but this slight increase was probably due to the 
longer coverage period of the study (six weeks).  
 
 
 
 
 
 
                                                 
∗
 This referred to the average monthly expense for April-June 2005, determined at R80 million/month from 
hospital expenditure sheets. 
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CHAPTER 4 
 
4.0 DISCUSSION & LIMITATIONS 
 
4.1 Discussion 
From the patient records reviewed there were larger numbers of adult patients as compared 
to children. Also more than half the adult patients were female, both amongst the HIV 
infected and non-infected patients. 
 
The median age of HIV Positive adults was shown to be 35 years; while the median age for 
HIV infected children was 8 months age (average age of children was under 2 years). 
 
The average length of stay for the 812 HIV positive cases included in this study was 
determined at 9.5 days (both adults and children). This had not changed significantly over 
the years when considering that the Karstaedt et al study of 1996 estimated an average of 
9.8 days for adult HIV positive cases. 
 
The results demonstrated that HIV positive patients were on average staying more than two 
days longer than HIV negative patients. HIV positive patients were also costing the 
hospital more than 35% the total cost of HIV negative cases. The reasons for this were: 
• Increased cost of investigations compared to HIV negative cases 
• More than double the expenditure on drugs compared to HIV negative cases 
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• The cost of the length of stay was higher due to the longer duration of stay, 
compared to HIV negative patients. 
 
When patients were classified as ‘Adults’ and ‘Children’, it was also noted that HIV 
positive adults and children stayed longer and had more resources spent on them than HIV 
negative cases. Also the common conditions for which HIV positive children had been 
admitted and discharged were Pneumonia and Gastroenteritis (Figure 3.3.2), whilst among 
adults it was predominantly Tuberculosis (Figure 3.3.1). For hospital and district managers 
this is an important point as it reiterates the fact that most of these conditions could have 
been preventable.  
 
Although the results showed that patients admitted in the tertiary care wards were costing 
the hospital more than those in Level 1 wards, this was obscuring the fact that the resources 
used to run the Level 1 wards were still tertiary, and hence the costs would still have been 
predictably higher than if treated at a district hospital. Regarding the appropriate use of 
resources, the justification of providing Level 1 services within a tertiary care hospital is 
quite debatable, considering the costs. The results also showed the common HIV infected 
conditions admitted and discharged in Level 1 wards, and again it was observed that the 
majority of cases were Pneumonia, Gastroenteritis and PTB. Whether or not the provision 
of Level 1 services within the hospital should be continued is another important 
consideration for hospital managers. 
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The study also highlighted the differences in cost amongst the HIV positive patients who 
were on ARV therapy. Those with Pneumonia and PTB were staying considerably longer, 
and also incurred more expenses from drugs and investigations. The data on ARV therapy 
collected from these patients only reflected that they were on therapy at the time. It was not 
an indication of prior commencement of ARV therapy. As such the reasons for the 
differences in costs and length of stay are complex and cannot be inferred from these 
results, as this was not part of the mandate of this study. However, one could probably 
presume that these patients were quite ill to begin with. They were therefore probably 
admitted for longer periods (and hence incurred higher costs from the increased lengths of 
stay), and were probably eligible to receive ARV therapy at the time as well.16 
 
The common conditions amongst HIV negative adults were more of Psychiatric disorders, 
Hypertension, and Cardiac problems. A profile of the double burden of infectious diseases 
(Tuberculosis, pneumonia, gastroenteritis) in the HIV positive group and chronic non-
infectious diseases in the HIV negative group was also quite evident. Amongst HIV 
negative children, as was expected; Pneumonia, Gastroenteritis, and respiratory tract 
infections topped the list. 
 
The main pharmaceutical cost drivers in HIV positive patients were shown to be 
antibiotics, IV fluids, Flucanozole, and blood transfusions. In terms of investigations and 
procedures, the cost drivers were Chest X-rays, scans (CT, sonars etc), special procedures, 
and HIV PCR tests. The study also described the common pharmaceutical items per patient 
in HIV and non-HIV patients (See table 3.9.1). Amounts spent on Augmentin were more or 
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less the same in HIV infected and un-infected patients, while Flucanozole, not surprisingly, 
was more than twice the cost in HIV positive cases. It was also determined that common 
tests like Chest X-rays, Full blood counts, and Urea & Electrolytes were significant 
expenses to the institute. In terms of frequencies of investigations too, it was determined 
that common tests such as Full blood counts and Urea & Electrolytes were performed two 
times more per HIV positive patient than in the non-HIV patient. Obviously more HIV 
PCR tests were done too, as for every test done on non-HIV cases, three tests were done 
for HIV positive patients. CT scans were done more frequently in the non-HIV cases, and 
Chest X-rays had similar frequencies.  
In comparison to the paper by Mathabathe et al, the hospital had spent approximately 65% 
more for drugs and investigations on the HIV positive patients included in the subject of 
this report. The reasons for the difference cannot be explained by this study, but could 
probably have been due to inflation increases or methodological variations. 
 
The numbers of HIV positive patients admitted ranged between 600-800 patients per 
month in 2005 for the whole hospital. It was not clear if these numbers had increased from 
previous years or not, however it was obvious from conversations with staff in the Medical 
and Pediatric departments that they felt they were seeing large increases in the numbers of 
HIV positive patients. Continued monthly and annual monitoring of this is essential to 
determine any change in trends rather than relying on anecdotal evidence.  
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The PDE cost was a financial performance indicator used by the Department of Health to 
determine if financial resources were being utilized efficiently15, and as such was not a real 
indicator of precise utilization per patient. Hence the use of a PDE cost to determine the 
costs of lengths of stay of the patients reviewed was a challenge. Patients have varying 
needs, and would thus utilize hospital resources very differently. By using the PDE cost in 
this study, the investigator attempted to distribute the indirect and some direct costs of 
resources evenly amongst all inpatients. The lower the PDE cost for the category of health 
facility, the greater the financial utilization and efficiency, as this meant more patients were 
being cared for within limited financial resources. The PDE cost, according to the 
Department of Health, thus varied according to the type of hospital with regards to level of 
care: 
Table 4.1.1: Average PDE costs∗ for the period April-June 2005 in hospitals in Gauteng Province.4 
 District 
Hospitals (n=8) 
Regional 
Hospitals (n=11) 
Central/Tertiary 
hospitals (n=4) 
Specialized 
Hospitals (n=5) 
E.g. TB hospital or 
Mental health 
facilities 
Average PDE 
costs 
R 824 R828 R1357 R 633 
 
From the above table, it could be observed that hospitals offering tertiary level services had 
a higher average PDE cost, indicating the significant expenses in terms of services 
rendered and patients seen. Again, this highlights the probable cost benefits of treating the 
common infectious diseases mentioned in this report at district hospital level, rather than at 
tertiary institute level.  
                                                 
∗
 These PDE costs were determined by dividing the total hospital expenditure by the total number of patient 
days seen for the period. Hence the value for tertiary hospitals is different from the PDE cost used in this 
study, where costs of pharmaceuticals & investigations were separated. 
4
 April-June 2005 Hospital Financial Indicators. As provided by the Directorate of Hospital services at 
Gauteng Health Department, 20 November 2006. 
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4.2 Limitations: 
• Not all patient records of discharges and deaths from the Medical and Pediatric 
departments were sent to the researcher, as explained in the Record Flow chart. 
This was as a result of lost or misplaced records; miscommunication between 
staff of where records should go; patients walking off with records; backlog of 
records in wards with no clerks etc. The shorter time frame of the study also 
probably had an influence. A sensitivity analysis may have been beneficial here 
in trying to determine the costs of the patient not included in the study, but since 
the proportion of HIV positive cases in the excluded records was not 
determined, this was not attempted. 
• Data was collected from individual patient records, which generally have a 
tendency to be incomplete and haphazardly entered. Therefore, the costs 
incurred by a particular patient were probably different to the true cost to that 
patient.  
• Since this was a cross-sectional survey over one short time period, seasonal 
variations in admissions could not be adjusted for. In addition, since the costs 
estimated were for a specified time period, this did not infer that the costs 
would be similar month after month. 
• The ARV rollout at the hospital only started in 2004, and the impact of the 
rollout was probably too early to evaluate. This study did not look at previous 
admissions, or when patients were actually put on ARV therapy. Therefore, the 
long-term cost savings of ARV therapy could not be determined in this project. 
The study could only cost what the patient was on at the time of the present 
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admission and discharge. As such, any differences in costs between patients on 
ARV therapy and those not on therapy have to be viewed with caution, and 
cannot be directly attributed to ARV drugs at this stage. 
• Estimations of indirect costs such as overheads; other consumables and non-
consumables; and costs for items such as staff salaries were determined from 
monthly financial expenditures and might not have been actual reflections of 
the costs accrued (it might have been more or less), since again hospital 
statistics, which could have been unreliable, were used for this calculation. The 
cost data for drugs, investigations and procedures was also not based on current 
prices, but on prices from 2002 and 2004, which may have been subsidized for 
government use. This again probably resulted in an underestimate of the true 
cost to the hospital in 2005.  
• The expenses incurred by the hospital have to be balanced against income 
generated from user fees, and extra funding from special grants such as the 
national allocation for the ARV roll out. This was not done in this study due to 
the complex way in which user fees are allocated to an institute, making it 
extremely difficult to calculate how much was received by the institute in terms 
of user fees. The funds for the ARV roll out cover costs of ARV drugs, which 
again were not balanced against the expenses incurred by the hospital. 
Therefore the estimates of the costs incurred were again probably not a true 
reflection of the actual costs. 
• Since this study was done only in one institute the results could not be 
generalized to other facilities or similar institutes in the public health sector. In 
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addition, since this was a tertiary institute costs may have been higher in 
comparison to other levels of care, and again could not be generalized to other 
levels of care. 
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CHAPTER 5 
 
5. CONCLUSIONS & RECCOMENDATIONS: 
 
5.1 Conclusions & Implications for Public Health: 
The study has managed to provide an estimate for the average costs of drugs, 
investigations, length of stay and costs of the length of stay for all the patients reviewed. 
Whether or not these amounts are reliable is a limitation of this study, especially 
considering the lack of similar studies in the country, although the paper by Karstaedt et 
al12 in 1996 used a similar methodology, but estimated only annual costs of admissions. 
 
The median ages of adults and children calculated in this study raise some relevant 
questions. How has HIV/AIDS affected the life expectancy of adults in comparison to 
chronic diseases? Even though the answer to this is beyond the scope of this study, it 
relates to the probable economic cost burden of HIV/AIDS on the country as a whole. 
Regarding the young age of HIV infected children, could this have been an indication of 
the success or failure of the Prevention of Mother To Child Treatment (PMTCT) program 
in the area? While again the answer to this question was beyond the scope of this study, it 
demonstrates the need for a multi-layered approach to address the HIV/AIDS epidemic in 
the hospital and surrounding area. 
 
The hospital had spent over R80 million per month on average during the period April-
June 2005 for all inpatients and outpatients across departments, and from the results it was 
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determined that HIV positive inpatients alone were contributing to roughly 6% of this 
amount. Yet according to the accounts department of the hospital, for the two months of 
May and June 2005, 19983 inpatients were admitted to the entire hospital across all 
departments, and these patients were only billed a sum total of R1.5 million for these eight 
weeks (provided by Mr. E Makhou, Accounting section, CHB).  Since the hospital is a 
public sector facility, it offers highly subsidized user fees for the patients, who are often the 
poorest of the poor, and quite commonly, most of the amounts billed are not recovered at 
all. Therefore, the expense to the hospital is obviously much higher, as also demonstrated 
by the costs of just the 812 HIV infected cases reviewed in this study. Also the longer a 
patient stayed, the more it cost the hospital, as more than 75% of the cost of care of a 
patient in this facility could be attributed to the cost of the length of stay. Shisana et al also 
highlighted this last point in their paper. 
 
The hospital could use the results of this study to advocate for more funds, demonstrating 
that HIV positive patients were staying longer and hence costing the hospital more. Having 
more money allocated to their ARV program and Prevention from Mother To Child 
Transmission (PMTCT) programs could also be argued for in terms of future budget 
allocations. In addition, the initial guidelines for the allocation of funds from the National 
ARV program only recommended funding for the diagnostic monitoring of those patients 
receiving ARV, listing not all, but a few specific laboratory investigations, the focus being 
on the mainly outpatient ARV roll out sites.17 Funding for investigations done on HIV 
positive inpatients who would eventually receive ARV therapy was not specified, but 
rather negotiated with institutes. The hospital could again use the results of this study to 
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show the increased usage of laboratory investigations by HIV positive inpatients, and 
lobby for more allocations from the national ARV program. With zero-based budget 
allocations appearing on the horizon, a far cry from the historical budget allocations of 
similar amounts year after year, the results of this study certainly arm the hospital with 
sufficient data to plan for some of their future financial needs and resource allocations. 
 
A study by Cleary et al evaluating the cost effectiveness of ARV therapy in South African 
patients, also showed that while providing ARV’s on the whole was economically 
worthwhile, the cost was still significantly higher than in those not on ARV’s. However, 
here the main costs were from the ARV drugs themselves and relevant laboratory tests.18 
The short to medium term economic impact of the ARV roll out on the hospital discussed 
in this dissertation, indicating increased costs of patients on ARV therapy, should be 
considered in the context provided. Hospital managers and policy makers who are involved 
in the roll out of such programs should be prepared and make allowances for this in their 
budget plans. 
  
It would have also been informative to compare total costs of conditions across various 
levels of care in the public health sector in South Africa, but since comparable data on this 
was unavailable, it was difficult to determine if the total costs to Chris Hani Baragwanath 
Hospital were significantly higher or not. Similarly, due to lack of comparable data at the 
time of the study it was not possible to evaluate if the costs of various conditions 
determined at Chris Hani Baragwanath Hospital were different to costs in the private sector 
in South Africa or not. 
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This study has highlighted the significance of understanding the financial burden of 
HIV/AIDS to hospitals and other health facilities. The 1996 study by Karstaedt et al12 
showed that the common admitting HIV/AIDS cases were Tuberculosis, acute pneumonia 
and diarrhoeal diseases. Ten years later not much has changed in this scenario. For hospital 
managers and policy makers this is an important finding as it again highlights the need for 
ensuring that scarce public health resources are used efficiently for services at the 
appropriate level of care. The use of tertiary care resources for cases that could have been 
managed at lower levels of care reflects on the inadequacy of the current district health 
system in the country and the need to strengthen it significantly. However, while the 
potential of a strong District Health System may add some relief to the hospital, it is also 
crucial to develop and implement the right guidelines and care packages needed for various 
levels of health care in South Africa. 
 
Developing an effective financial tracking system is an essential component of determining 
costs of cases seen. Most of the large private hospital groups in South Africa have 
reasonably functioning systems in place19, and it is probably well past the time for the 
public sector in this country to follow suit. The cost of implementing such a system, in the 
face of poor user fee collections and government subsidies, could be a bone of contention 
among decision makers. However budget allocation cannot and should not occur in a void, 
and managers need to know how and where resources are being utilized. 
The challenge for hospital managers and policy makers is in addressing the issue of 
HIV/AIDS services at appropriate levels of care, without appearing to offer fewer services 
to the surrounding communities. 
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5.2 Recommendations 
While South Africa is battling to get a grip on the HIV/AIDS epidemic, it is certainly not 
an impossible task, as has been shown with the successful results in Brazil. The South 
American country has managed to reduce the social and economic impact of HIV/AIDS 
since 1996 when universal and free access of anti-retrovirals was introduced. Local and 
cheaply produced ARV’s were the main reason for the Brazilian government’s policy to 
provide free ARV treatment to all. This has resulted in a cost saving of US$ 677 million in 
terms of avoided hospital admissions since 1996. Coupled with other programs such as 
PMTCT, active health education, promotion, increased condom usage etc, Brazil has 
managed to considerably decrease their death rates due to HIV infection, and slow the 
spread of the infection.20 
 
For health systems managers, policy makers and facility managers, it is important to realize 
what areas to focus on in trying to reduce the burden of HIV/AIDS on the health sector. 
The following are a number of issues that could be highlighted as possible 
recommendations to help reduce costs in this regard: 
 
Changes at hospital level: 
• Ensuring that the right cases get admitted to the facility. This entails 
having an adequate referral system where less complicated and 
common conditions can be treated at lower levels of care. This also 
ensures that the resources in the tertiary level hospital are being 
utilized efficiently.  
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• Decreasing the length of stay of patients, where possible. In this 
study the bulk of the cost was the PDE cost from the increased 
duration of stay. This has to be seriously looked at, either in terms of 
using step-down facilities, or quicker discharges of patients if 
possible. 
• Development of standard protocols to avoid duplication of 
investigations and procedures. 
• Re-evaluation of the Level 1 service offered in this hospital. While 
the idea behind the creation of Level 1 wards was to reduce the load 
on the main Medical Wards, one cannot escape the fact that tertiary 
level resources and thus costs are being used to run this service. 
Hence the probability of phasing out this service or merging it with a 
District Hospital should be seriously considered. 
• Support and resources for the provision of ARV therapy. While the 
findings in this study showed increased costs and lengths of stay for 
those patients on ARV therapy, this could merely have been a 
reflection of the extent of illness, and did not necessarily rule out the 
benefits of ARV therapy. Providing ARV therapy would result in a 
healthier HIV Positive population that in the long term may require 
lesser and shorter admissions20. The ARV rollout commenced in 
April 2004 in the hospital and surrounding district, but the impact of 
this in terms of affecting hospital admissions is still to be 
investigated in depth. Since the rollout began, only 10% of all the 
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HIV positive patients seen in the district have been put on ARV’s till 
date. (ART Rollout Report 02 Sept 2005. Health Information 
Department, 17th floor, Gauteng Health Department) 
• Anti-TB prophylaxis to eligible HIV positive patients. A significant 
number of the HIV positive cases in this study had some form of 
Tuberculosis. Anti-TB prophylaxis could well be of benefit to the 
hospital in the long term. This is scope for future research as well. 
• An effective financial tracking system. Currently the hospital has no 
way of knowing what has been spent on a patient. It follows that 
having a system to track costs would definitely be of benefit to the 
hospital managers. Health care workers along with other relevant 
staff need to capture all the costs related to a patient, which in itself 
is another challenge that needs to be addressed first. 
 
Changes at district level: 
• Support of a strong and effective District Health System. It follows   
that having less people infected with the HIV virus is the key to 
reducing the burden of the infection on the system. Health Promotion 
and Preventive campaigns need to be strengthened and heightened. 90% 
of all clinics and 100% of the hospitals in the district concerned offer 
PMTCT services, yet the impact of this in terms of preventing mother to 
child transmission of HIV infection is still unclear in the area (PMTCT 
1st Quarter Report April-June 2005. Mrs L Mnisi, Deputy Director, 
 48 
HAST Directorate, Gauteng Department of Health). More focus on 
developing strategies to ensure adequate follow up of PMTCT mothers 
and babies is also crucial. 
• Fast tracking and addressing the challenges in accreditation of 
clinics to ensure the provision of ARV therapy within the district. This 
again should in the long run ensure a ‘healthier’ HIV infected 
population, thus reducing the burden on the hospital.  
• Provision of anti-TB prophylaxis to eligible HIV positive patients. 
This again highlights the importance of a multi-collaborative approach 
and a strong District Health system. While INH prophylaxis for HIV 
positive patients is strongly recommended by the World Health 
Organization guidelines, and as a result, now part of South African 
National TB guidelines21, implementation is still a huge challenge. 
 
Changes at National/Provincial level: 
• Negotiating with Pharmaceuticals to reduce prices of ARV drugs, 
and other relevant drugs. 
• Creating opportunities in South Africa to manufacture low-cost, 
effective generic drugs as in countries like India and Brazil. 
• Development of an effective financial tracking system that can be 
incorporated nationally. 
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APPENDIX I: 
CHRIS HANI BARAGWANATH HOSPITAL 2005 COSTING STUDY – CODES & 
COSTS 
 
 
Code Investigation Cost (In Rands) 
     
01 CXR 96 
02 CT Scan 1524 
03 USS 267 
04 FBC 34.95 
05 Diff 22.16 
06 U&E 84.4 
07 LFT 207.86 
08 ESR 15.03 
09 Ca Mg PO4 70.31 
10 HIV Rapid 39.95 
11 HIV Elisa 80.75 
12 HIV PCR 429.57 
13 Viral Load 300 
14 Glucose 20.49 
15 CRP 49 
16 Bld cult aerobic 79.64 
17 Bld cult anaerobic 79.64 
18 Sputum AFB x 2 28.04 
19 TB Bactec 14.09 
20 CSF 115.42 
21 Hep A 82.99 
22 Hep B 82.99 
23 Hep C 82.99 
24 TFT 214.89 
25 Urine MC&S 146.12 
26 Lipase 29.33 
27 ALT 30.6 
28 CD4 60 
   
Code Procedure Cost (In Rands) 
    
40 Bone Marrow 149.04 
41 Liver Biopsy 62.55 
42 Pleural Tap 62.55 
43 Ascetic Tap 62.55 
44 Biopsy Lymph node 62.55 
45 Biopsy Skin 62.55 
 3 
46 Bronchoscopy 2942 
47 Gastroscopy  2942 
48 Echocardiogram 332 
49 ECG 350 
50 EEG 2050 
51 EMG 2685 
 
 
Code Drug name Dosage Cost (In Rand) 
  
      
100 Acetylycysteine/Parvolex inj 200mg/ml 9.9/ml 
101 Acyclovir injec/Zovirax 250mg 76.22 
102 Acyclovir oral 400mg 0.87 
103 Acyclovir syrup 200mg 10.2 
104 Adalat/Nifedepine 30mg 0.95 
105 Akineton inj 5mg 13.27 
106 Aldactone 100mg 4.7 
107 Aldomet 250mg 0.25 
108 Allergex tab  4mg 0.06 
109 Amikacin injection 100mg 7.9 
110 Amikacin injection 250mg 10.74 
111 Amikacin injection 500mg 8.89 
112 Amikacin injection 1gm 27.46 
113 Aminophylline 250mg/vial 1.17 
114 Amoxil oral 250mg 0.16 
115 Amoxil oral 500mg 0.38 
116 Amoxil syrup 125mg/ml 4.11 
117 Amoxil syrup 250mg/ml 6.26 
118 Amphogel 10ml 0.03 
119 Ampicillin injection 250mg/vial 1.19 
120 Asprin/Disprin 300mg 0.12 
121 Asthma pumps (Becotide) one spray 15.03 
122 Atenolol tab 100mg 0.43 
123 Atrovent Nebs Nebs 1.7 
124 Augmentin injection 0.6gm vial 14.13 
125 Augmentin IV 1.2gm 24.4 
126 Augmentin oral 375mg 1.63 
127 Augmentin syrup 5ml 0.8 
128 AZT syrup 50mg/5ml 0.72 
129 AZT/Zidovudine 300mg 1.6 
130 Bactrim inj 80mg 3.75 
131 Bactrim oral I tab 0.12 
132 Bactrim oral tablet 0.12 
133 Bactrim syrup (50ml) 48mg/ml 0.03 
134 Berotec syrup 2,5mg 0.6 
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135 Betaphen/Penicillin oral 250mg 0.18 
136 Brufen syrup 100mg 0.43 
137 Brufen tab 200mg 0.06 
138 BUSCOPAN 10MG 0.4 
139 Buscopan syrup 5mg 1.13 
140 Cefepime injection 500mg 41.97 
141 Cefotaxime IV 500mg 7.49 
142 Cefoxitin injection 1gm 37.2 
143 Ceftazidime injection 500mg 65.76 
144 Ceftazidime injection 1gm 74.54 
145 Cefuroxime injection 250mg 12.72 
146 Chlorampheniocol oral 250mg 0.39 
147 Chlorampheniocol/Cloromycetin inj 1gm 9.58 
148 Ciprobay IV 2mg 1.3 
149 Ciprobay oral 250mg 0.37 
150 Ciprobay oral 500mg 0.46 
151 Claforan inj 500mg 7.47 
152 Clarforan IV 1gm/vial 9.9 
153 Clarithromycin 500mg 16.9 
154 Cloxacillin injection 500mg 4.52 
155 Cloxacillin oral 250mg 0.31 
156 Cloxacillin oral 500mg 0.47 
157 COVERSYL     
158 Cyclokapron 500mg 0.3 
159 D4T syrup 1mg/ml 0.4 
160 D4T/Stavudine 20mg 0.6 
161 D4T/Stavudine 30mg 0.5 
162 D4T/Stavudine 40mg 0.4 
163 Daktarin     
164 Decadron inj 4mg  4.73 
165 Decadron IV 4mg/vial 4.73 
166 Decadron oral 05mg 0.34 
167 Diamicron 80mg 0.16 
168 DIAZEPAM 5MG 0.07 
169 Diazepam inj 5mg 1.03 
170 Diclofenac inj 25mg 0.24 
171 Diclofenac/Voltarin 50mg 0.22 
172 Digoxin 0.25mg 0.17 
173 Digoxin syrup 0.05mg/ml 0.78 
174 Digoxin inj 0.25mg 6.59 
175 Doxycycline oral 100mg 0.14 
176 Efavirenz/Stocrin 200mg 3.47 
177 ENALAPRIL/RENITEC 5MG 0.1 
178 EPANUTIN ORAL 100MG 0.27 
179 Epanutin oral 100mg 0.27 
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180 Epanutin syrup 125mg/ml 3.5 
181 Epanutin/Phenytoin IV 50mg/ml 10.53 
182 Epilim syrup 200mg 1.6 
183 Erythromycin IV 1gm 120.08 
184 Erythromycin oral 250mg 0.64 
185 Erythromycin syrup 125mg 0.5 
186 Etomine inj 10mg 0.37 
187 Etomine oral 40mg 1.62 
188 Fentenol spray   20.86 
189 Flagyl IV 500mg/ml 0.05 
190 Flagyl oral 400mg 0.16 
191 Flagyl syrup 40mg/ml 0.15 
192 Flixotide spray one spray 45.19 
193 Flucanozole IV 2mg 0.1 
194 Flucanozole tab 200mg tablet 19 
195 Flucanozole tab 50mg 10.35 
196 Folic acid tab 5mg 0.05 
197 Fungizone tablets/Amphotericin one tablet/10mg 2.23 
198 Gentamycin injection 10mg/ml 1.32/ml 
199 Glucophage 500mg 0.13 
200 Glucophage 850mg 0.26 
201 Glycomin 5mg 0.06 
202 Griseofulvin 500mg  1.22 
203 HCTZ/RIDAQ 25MG 0.1 
204 Heparin injection 5000u/ml 8.72 
205 Immodium 1 tab 0.09 
206 Immodium one tablet 0.09 
207 Immodium syrup 1mg/5ml 0.57/5ml 
208 Insulin/Actraphane 100 UNITS/ML 6.94 
209 Insulin/Actrapid 100u/ml 7 
210 Insulin/Humalog 100u/ml 13.8 
211 
Insulin/Humulin N/Humulin R/Humulin 
30:70 100u/ml 5.7 
212 Insulin/Protophane 100u/ml 10.6 
213 Iron tablet one tab 0.06 
214 Isoptin/Verapamil 240mg 0.1 
215 KCL injection diluted 1 vial (10mls) 1.72 
216 Keflex oral 250mg 0.37 
217 Keflex syrup 250mg 0.56 
218 Kefzol injection 500mg 3.56 
219 Keyexalate 1gm 0.896 
220 Klacid inj 500mg 119.01 
221 Klacid syrup 125mg 0.69 
222 Lamivudine/3TC 150mg 0.6 
223 Lamivudine/3TC syrup 10mg/ml 1.15 
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224 Largactil syrup 25mg 0.5 
225 Largactil tab 50mg 0.1 
226 Lasix 40mg 0.08 
227 Lasix IV 10mg 0.5 
228 Lipitor 10mg 4.6 
229 Lorazepam injection     
230 Maxalon injection 10mg 1.31 
231 Maxolon oral 10mg 0.04 
232 Melleril oral  50mg 0.31 
233 Minoxidil tab 10mg 0.4 
234 Mist Expect 1 bottle 2.74 
235 Mist Pot KCL     
236 Morphine injection 15mg/ml 1.73 
237 Multivitamins syrup one bottle 15.12 
238 NaHCO3 inject 50ml 23.93 
239 Nevarapine 200mg 1.1 
240 Nystatin syrup 1drop 0.27 
241 Otosporin drops 1 drop 0.3 
242 Panado oral 500mg 0.05 
243 Panado syrup (100ml) 120mg/5ml 0.03/ml 
244 Pen G injection 2.4 MU/vial 3.12 
245 Pen G injection 1.2 MU 3.49 
246 Pethidine inj 50mg 2.39 
247 Phenergan injection 25mg/ml 1.36 
248 Phenergan oral 10 mg  0.05 
249 Phenergan syrup 5mg/5ml 0.34/5ml 
250 Phenobarb injection 200mg 9.67 
251 Phenobarb tab 30mg 0.09 
252 Prednisone oral 5mg 0.06 
253 Prednisone syrup 15mg/ml 0.7 
254 pyridoxine oral 25mg 0.09 
255 Rifafour one tablet 0.88 
256 Rifanah Junior 3gm/sachet 1.04 
257 Rim Cure one tablet 0.82 
258 Rivotril inj 1mg 18.25 
259 Rocephin IV 1gm 13.17 
260 Salbutamol inj 1mg 17.4 
261 Salbutamol syrup 2mg 0.18 
262 Salbutamol tab 2mg 0.09 
263 Salbutamol/Ventolin spray one spray 14.32 
264 Seranace inj 5mg 17.42 
265 Solucortef injection 100mg 7.34 
266 Spectrapain one tablet 0.14 
267 Stemetil inj 12.5 mg 2.75 
268 Stemetil oral     
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269 Tazocin/Piperacillin inj 2gm 39.04 
270 Tegretol/Carbamazepine injection  
100mg/5ml in 
250ml 83.56 
271 Tegretol/Carbamazepine oral 200mg 0.17 
272 Theophylline syrup/Neulin 25mg 0.35 
273 Thiamine injection 100mg/ml 1.3 
274 Thiamine oral/Vit B complex 100mg 0.01 
275 Tobramycin inj 40mg 5.2 
276 Tramadol oral 50mg 0.48 
277 Tritace/Ramipril 2.5mg 0.9 
278 Tryptanol/amitriptyline oral 25mg 0.1 
279 Vancomycin inj 500mg 50.94 
280 Vit A  tab 50 000u 1.39/tab 
281 Vit B complex tab 0ne tab 0.02 
282 Vit B syrup one bottle 2.29 
283 Vit B12 inj 1ml 1.7 
284 Vit C injection 100mg/ml 0.05 
285 Vit C tab 500mg 0.15 
286 Vit K tab 10mg 4.1 
287 Zantac inj/Ranitidine 25mg 0.7 
288 Zantac syrup/ranitidine 150mg 7.8 
289 Zental syrup/Albendazole 100mg 2 
290 Zinnat syrup 125mg 0.46 
 
 
Code LAB Tests Cost (In Rand) 
      
400 17-Alpha-Hydroxy-Progesterone      74.43 
401 Abnormal Haemaglobin               83.72 
402 ABO Group Rh                       21.6 
403 Acetoaminophen Level    64.71 
404 Acetylcholine Receptor A/B         95.94 
405 Acid Phosphatase Cellular          31.05 
406 Activated Protein C Resistance     155.88 
407 Additional Cytogenetic Analysis     453.53 
408 Adenosine Deaminase                30.6 
409 Adenosine Deaminase - M            30.6 
410 AHG Inhibitors                     344.97 
411 Alanine Transaminase - A           30.6 
412 Albumin - A                        27.2 
413 Alcohol (In Blood ) - M            70.21 
414 Aldolase - A                       30.6 
415 Aldosterone                        74.43 
416 Alpha 1 Antitrypsin - M            40.8 
417 Alpha Feto-Protein R I A           71.12 
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418 Amicacin level                     64.71 
419 Ammonia - M                        43.61 
420 Ammonia (Ammonia Monitor)          25.5 
421 Amylase -M                         29.33 
422 Amylase Total - A                  29.33 
423 ANA (Hep 2 Cells) Screening        91.68 
424 Anaerobe Confirmatory Screen       25.8 
425 Anaerobes Id Finegold              56.67 
426 Androstenedione Ria                74.43 
427 Angiotensin Convert Enzyme M       50.92 
428 Anti-DNAse B                       44.85 
429 Anti-Gastric Parietal              91.68 
430 
Antigen Detection with Monoclonal 
Antibodies 61.83 
431 Anti-Mitochondrial Fluorescent     91.68 
432 Anti-Nuclear Factor Fluorescent    91.68 
433 Anti-Proteinase 3 Ab's             91.68 
434 Anti-Smooth Muscle Ab's            91.68 
435 Antistreptolysin O - Macro         49 
436 Antithrombin Iii Chromogenic       131.85 
437 Aspartate Transaminase - A         30.6 
438 Aspiration Performance Only        109.44 
439 Automated Bld Cult Aerobic Growth  79.64 
440 
Automated Blood Cult Anaerobic 
Growth 79.64 
441 B12 vitamin Assay            74.43 
442 Bactec MGIT bottle                 14.09 
443 Barbiturates Spectro - M           64.71 
444 Benzodiazepines - Emit S Qn        64.71 
445 Beta Lactamase Test                25.8 
446 Beta-2 Microglobulin               73.6 
447 BHCG Titre Profile                 70.21 
448 Bilharzia Elisa Test               74.13 
449 Bilharzia Fluorescent -IgG         68.71 
450 Bilharzia Fluorescent -IgM         68.71 
451 Bilharzia Microscopic              28.04 
452 Bilirubin Direct Automated         18.08 
453 Bilirubin Total - A                23.85 
454 Biochem ID Bacterium Abridged      18.06 
455 Biochem ID Bacterium Extended      71.64 
456 Bleeding Time-Excl Simplate        41.58 
457 Bone Marrow Cytological            125.88 
458 Bone Marrow Trephine (Biopsy)      206.25 
459 Brucella Abortus Agglutination     31.48 
460 B-type Natriuretic Peptide         281.06 
 9 
461 Buffy Layer Examination            113.95 
462 Ca-125 Tumour Marker               119.88 
463 Ca-19.9 Tumour Marker              119.88 
464 Caeruloplasmin - M                 25.5 
465 Calcitonin                         107.64 
466 Calcium - A                        20.49 
467 Calcium Ionized                    38.25 
468 Cannabinoid - Emit                 64.71 
469 Carbamazepine Level                61.12 
470 Carcino Embryonic Antigen Ria      114.55 
471 CD10 Common All Marker/Nep         115.21 
472 CD103 Hairy Cell Markers           115.21 
473 CD117 Stem Cell Factor Recepto     115.21 
474 CD11b Monocyte/Myeloid Marker      115.21 
475 CD11c Hairy Cell Leukaemia Mar     115.21 
476 CD13 Late Myeloid Marker/Amp       115.21 
477 CD14 Monocyte Marker               115.21 
478 CD15 Granulocyte Marker            115.21 
479 CD19 Early To Late Pan B Marker    115.21 
480 CD2 Pan T Cell/Nk Marker           115.21 
481 CD20 Late Pan B Marker             115.21 
482 CD22 B Marker ; Precursor          115.21 
483 CD23 FCE Receptor/B-CLL Marker     115.21 
484 CD25 Il2 Receptor Hcl Marker       115.21 
485 CD3 Pan T Cell Marker              115.21 
486 CD30 Ki1 Reed Sternberg Cell M     115.21 
487 CD33 Early Pan Myeloid Marker      115.21 
488 CD34 Haematopoietic Precursor      115.21 
489 CD38 Plasma Cell Marker            115.21 
490 CD4 Helper T Cell Marker           115.21 
491 CD4 PLG                            60 
492 CD45 LCA White Cell Marker         115.21 
493 CD45ra Naive T Cell Marker         115.21 
494 CD5 Pan T Cell/B-Cell Marker       115.21 
495 CD56 Ncam Nk Marker                115.21 
496 CD7 Early to late Pan T Cell       115.21 
497 CD8 Suppressor T Cell Marker       115.21 
498 Cell 1 Culture                     91.68 
499 Cell Culture 1                     97.19 
500 Cell Culture 2                     291.56 
501 Cellognost - Amoebiasis            56.67 
502 Chloride - A                       14.62 
503 Chloride C                         14.62 
504 Chlorides Colourimetric            14.62 
505 Cholesterol HDL - A                39.1 
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506 Cholinesterase Total - M           42.33 
507 Chromosome Analysis 1              874.67 
508 Chromosome Analysis 2              1749.33 
509 Chromosome Studies Bone Marrow     1749.33 
510 CI Esterase Inhibitor              91.68 
511 Citrate Agar Electrophoresis       160.74 
512 Clostridium Difficile Toxin        171.83 
513 CMV IgG Elisa                      74.13 
514 CO2 Content -A                     29.33 
515 Combined Antigen Specific IgE      140.18 
516 Complement C3                      49 
517 Complement C4                      49 
518 Complement Comp C6                 20.64 
519 Copper Atomic Absorption           108.63 
520 Cortisol                           74.43 
521 Coxsackie Virus Ab (1st)           429.57 
522 C-Peptide Ria                      70.3 
523 C-Reactive Protein (Ultra sens)    65.78 
524 C-Reactive Protein Nephelometer    49 
525 Creatine Kinase - A                32.4 
526 Creatine Kinase M-B -A             32.4 
527 Creatinine - A                     20.49 
528 Cryoglobulin Qual - M              20.4 
529 Cryptococcal Latex                 31.48 
530 Cryptococcus Titration             31.48 
531 CSF Cell Count                     19.78 
532 CSF Culture - Growth               36.12 
533 CSF Culture - No Growth            36.12 
534 CSF Micro                          28.04 
535 Culture Aerobic                    36.12 
536 Culture Anaerobic                  25.8 
537 Culture Campylobacter Fetus        56.67 
538 Cysticercosis EIA                  74.13 
539 Cytomegalovirus Dir If (Rapid)     68.71 
540 D-Dimer (Xdp Test) Semi Quan       50.94 
541 D-Dimer Quantitative               164.97 
542 Diff Count and Comment Manual      22.16 
543 Digoxin Level Abbot Tdx            74.43 
544 Dihydroepianrostene Sulphate       74.43 
545 Direct Coombs Test                 21.87 
546 Disc Sensitivity (Per Org)         45.84 
547 Disc Susceptibility test Mycology  45.84 
548 DNA Crithidia Fluorescent          91.68 
549 DNA Extraction                     263.93 
550 DNA Ploidy Flow Cytometry          126.45 
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551 EasyQ Viral Load                   300 
552 EBV Ebna                           38.7 
553 EBV IgM                            80.5 
554 Echinococcal Haemagglutination     56.67 
555 EIA for ACLA IgG                   74.13 
556 EIA for ACLA IgM                   80.5 
557 Electron Microscopy                649.23 
558 Electrophoresis Qualitative        25.5 
559 Electrophoresis Qualitative        25.5 
560 Elisa for TB Antibody IgM          74.13 
561 Elisa TB Antibody IgG              74.13 
562 Enzyme-Linked Immunoassay          71.04 
563 ESR                                15.03 
564 EXF Cytology  Additional Unit      56.91 
565 EXF Cytology (Gynae) 1st Smear     80.28 
566 EXF Cytology (Gynae)1st&2nd Smear  160.55 
567 Exfoliative Cytology (General)     97.76 
568 Factor B Radial Immunodiff         18.06 
569 Factor IX Xmas Assay               193.05 
570 Factor V Assay                     193.05 
571 Factor VII Assay                   193.05 
572 Factor VIII Assay                  193.05 
573 Factor VIII Related Antigen        362.43 
574 Factor X Stuart Prower             193.05 
575 Factor XI Assay                    193.05 
576 Factor XII Assay                   193.05 
577 Faeces General Parasitology        28.04 
578 Ferritin Assay Ria           74.43 
579 Fibrinogen Degradation Product     26.92 
580 Fibrinogen Quantitative            21.6 
581 Fine Needle Aspiration Cytology    357.49 
582 FISH Analysis                      226.77 
583 FISH Preparation                   453.53 
584 Fluorescent Treponemal (TFA)       68.71 
585 FMC7 Non Hodgkins Lymphoma Mar     115.21 
586 Folate (serum)                       74.43 
587 Follicle-Stimulating Hormone       74.43 
588 Free Hormone (T.3)                 98.94 
589 Frozen Section In Lab              156.75 
590 Full Blood Count Incl Platelet     34.95 
591 Fungal Cultures                    25.8 
592 Fungal Identification              71.64 
593 G6PD Fluorescent Screen Test       47.97 
594 Gastrin                            74.43 
595 Genotype Per Person PCR            388.74 
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596 Gentamicin Levels                  70.11 
597 Gentamicin Levels                  70.11 
598 Glucose - A                        20.49 
599 Glutamyl Transpeptidase - A        30.6 
600 Glycated  Haemoglobin - A          40.8 
601 Glycophorin-A Red Cell Marker      115.21 
602 H & E Stain By Linear Staining     46.27 
603 Haemoglobin Alkali Resistant       27 
604 Haptoglobin - M                    53.47 
605 Hb Electrophoresis Qual            160.74 
606 Hb Only                            11.04 
607 Hb-H by Staining Method            13.5 
608 HCG Monoclonal - Qual              56.81 
609 Hepatitis per antigen              82.99 
610 Herpes EIA IgG                     74.13 
611 Histochemical Studies Group 1      142.98 
612 Histochemical Studies Group 2      142.98 
613 Histology 1 Additional Block       80.09 
614 Histology 1 Block                  138.13 
615 Histology-PCR                      388.74 
616 HIV  Elisa                         80.75 
617 HIV PCR                            429.57 
618 HIV Rapid Screen Test              39.95 
619 HLA Dr Marker                      115.21 
620 Human Growth Hormone - Hgh         74.43 
621 Human IgG Subclasses               119.88 
622 Identification Mycobacteria        56.67 
623 IgG specific Ab titre: ELISA/EMIT  74.13 
624 Immmunophenotyping per marker      115.21 
625 Immunofluorescence                 142.98 
626 Immunoglobulins IgA - A            43.95 
627 Immunoglobulins IgE - Total        74.43 
628 Immunoglobulins IgG - A            43.95 
629 Immunoglobulins IgM - A            43.95 
630 Immunoperoxidase                   276.26 
631 Immunosuppressant Drugs            124.11 
632 Indirect Fluorescent Test          142.98 
633 INR (PTT Correction Studies)             66.39 
634 Insulin                            74.43 
635 Intrinsic factor                   74.43 
636 Iron - A                           40.5 
637 Kinyoun Stain for Mycology         47.56 
638 LA/SSB Od Ratio                    91.68 
639 Lactate - A                        61.12 
640 Lactate Dehydrogenase Total        30.6 
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641 Lipase -M                          29.33 
642 Lithium Flame Emission             31.05 
643 Luteinizing Hormone -Lh-           74.43 
644 Macroduct and Pilogel              181.56 
645 Magnesium Colorimetric - A         20.49 
646 Malaria                            32.08 
647 Malaria Rapid Kit                  56.91 
648 Measles IgG (Elisa)                74.13 
649 Measles IgM (Elisa)                80.5 
650 MIC MBC Kill (MIC or Tube)         70.11 
651 Micro TB Misc.                     17.2 
652 Micro TB Misc. Fluor               28.04 
653 Microalbumin In Urine              70.3 
654 Microscopy Only Stained Prep       28.04 
655 Microscopy Only Wet Prep           28.04 
656 Mucopolysacharides Quan            94.91 
657 Mumps IgM                          80.5 
658 Mumps Virus IgG                    73.87 
659 Mycoplasma IgG                     74.13 
660 Mycoplasma IgM                     80.5 
661 Myoglobin Ria                      74.34 
662 Myoglobulin Qual - M               70.21 
663 Neuropathological Examination      756.3 
664 Nor-Metanephrine Hplc Profile      442.26 
665 Occult Blood - Qual - M            12.75 
666 Oestradiol Total                   74.43 
667 Osmolality - M                     38.25 
668 P M Exclude Histopathology         799.05 
669 Panel Typing                       206.23 
670 Para Protein - Immuno Fixation     265.37 
671 Parathyroid Hormone                102.42 
672 Parvovirus IgG ABS                 74.13 
673 PCV                                10.8 
674 Perinuclear Ab's                   91.68 
675 pH                                 5.1 
676 Phenobarbitone Emit - A            64.71 
677 Phenytoin Levels Abbot             64.71 
678 Phosphatase Alkaline - A           29.33 
679 Phosphorus - A                     20.49 
680 Plasma Catecholamines By Hplc      468.27 
681 Plasma Renin Activity - Pra        113.31 
682 Platelet Count - Manual (1)        13.5 
683 Pneumocystis IFA                   68.71 
684 Polymerase Chain Reaction (PCR)         380.02 
685 Porphobilinogen - Quant            84.92 
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686 Porphyrins Quant M                 113.22 
687 Potassium - A                      20.49 
688 Prenatal Genotype PCR              777.48 
689 Profile Gases and pH-Automated     102.55 
690 Progesterone                       74.43 
691 Prolactin                          74.43 
692 Prostatic Specific Antigen         86.85 
693 Protein C Assay                    181.53 
694 Protein Electrophoresis -Quan      63.67 
695 Protein Electrophoresis Quan M     50.92 
696 Protein S Assay                    224.82 
697 Protein Total - A                  17.6 
698 Protein Total M                    17.6 
699 Prothrombin Index Pi Manual        30 
700 PTT Test                           33.15 
701 Pyruvate - M                       25.5 
702 R/M Culture TB                     62.55 
703 R/M Culture TB No Growth           62.55 
704 
Radiometric Mycobact Antibiotic 
Sensitivity 143.19 
705 Rast Test each Allergen            71.12 
706 Red Cell Folate                    104.76 
707 Releasing Hormone Response         299.7 
708 Respiratory Syncitial Virus        200.47 
709 Reticulocyte Count                 18 
710 Rh Only                            21.6 
711 Rheumatoid Factor Neph             49 
712 Rickettsial Agglutination          31.48 
713 Ristocetin Co Factor               193.05 
714 RNP Od                             91.68 
715 RPR Quantitative Slide             20.64 
716 RPR Slide Test                     12.9 
717 Rubella IgG/IMX                    74.13 
718 Rubella IgM Elisa                  80.5 
719 S H B G                            74.43 
720 Salicylates (Abbot Tdx)            64.71 
721 Salmonella Typhi Agg               31.48 
722 Sens Mother Antibody Invest Bl     30 
723 Serological Id of bacteria: abridged 18.06 
724 
Serological Identification of bacteriu: 
extended 58.39 
725 Serotyping of Meningococci         58.39 
726 Serotyping of Streptococci         41.8 
727 Shell Vial Cult Cytomegaloviru     91.68 
728 SLE Inhibitors                     149.85 
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729 Smith Od Ratio                     91.68 
730 Sodium                             20.49 
731 Special Stains                     43.83 
732 Stains Group 1 Cresyl Violet Etc   46.27 
733 Stains Group 2 Solochrome Etc      46.27 
734 Stains Group 3                     46.27 
735 Surface Kappa LC Marker            115.21 
736 Surface Lambda LC Marker           115.21 
737 Sweat Chloride Electrode           14.62 
738 Testosterone Total                 74.43 
739 Theophyline Level (Abbot Tdx)      64.71 
740 Thrombin Time                      42.93 
741 Thyroglobin Haemagglutination      56.67 
742 Thyroglotulin                      74.43 
743 Thyroid Fluorescent                68.71 
744 Thyroid Function Profile           214.89 
745 Thyroid Haemagglutination          56.67 
746 Thyroid Stimulating Hormone        117.45 
747 Thyroxine Free -Free T4            98.94 
748 Tobramycin - Emit                  64.71 
749 Toxocara Canis Eia                 71.12 
750 Toxoplasma EIA Test                74.13 
751 Toxoplasma Titre IgM               80.5 
752 Transferrin - A                    66.22 
753 Treponema Haemagglutination        56.67 
754 Tricyclic -Emit S.Qn               64.71 
755 Triglyceride -A                    44.88 
756 Troponin T                         113.22 
757 U&E      84.4 
758 Urea - A                           20.49 
759 Uric Acid Automated                21.42 
760 Urine Bacterial Inhibition         21.76 
761 Urine Culture                      36.12 
762 Urine Dipstick & screening tests                8.5 
763 Urine Microscopy                   28.04 
764 Valproic Acid Levels               64.71 
765 Vancomycin Levels                  70.11 
766 Vanillyl Mand Acid Qual Elect (VMA)    67.41 
767 VDRL Quant Slide (8 Dilutions)     20.64 
768 Viable Cell Count                  7.74 
769 Viral Load                         482.8 
770 Virus neutralisation each add.Ab   85.91 
771 Virus PCR                          429.57 
772 Vitamin A - M                      37.8 
773 Vitamin D (Ria)                    449.55 
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774 Vitamin E - M                      21.6 
775 WBC Only - Automated               11.04 
776 Western Blot for ANA/ENA           423.81 
777 Yeast ID Auxanogram                71.64 
778 Yeast ID Disc Method               18.06 
779 Yeast ID Germ Tube Test 1          18.06 
780 Yersinia Serology                  31.48 
781 Zinc Atomic Absorption             108.63 
 
FLUIDS & BLOODS PRODUCTS 
(per unit)  
782 Whole blood (per unit) 811 
783 Packed cells/red cell concentrate 733 
784 Fresh frozen plasma 586 
785 Platelets (adult) 3728 
786 Pediatric Platelet concentrate 2619 
789 Autologous blood 848 
790 Stem cell concentrate 5069 
791 Vaculitre (1 litre) 38.74 
792 Vaculitre (2 litre) 43.03 
793 Jelco 2.96 
794 IV set 1.24 
 
 
 
 
